Patents by Inventor Els Verhoeyen
Els Verhoeyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348934Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Medicale (INSERM), Centre National de la Recherche ScientifiqueInventors: Caroline COSTA FEJOZ, Els Verhoeyen, François-Loîc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Publication number: 20230340085Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence compris -ing successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the spli -cing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a se -quence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunType: ApplicationFiled: February 24, 2023Publication date: October 26, 2023Inventors: Floriane FUSIL, Els VERHOEYEN, Thierry DEFRANCE, François-Loïc COSSET
-
Patent number: 11623950Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobuType: GrantFiled: July 8, 2016Date of Patent: April 11, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE LYONInventors: Floriane Fusil, Els Verhoeyen, Thierry Defrance, François-Loïc Cosset
-
Patent number: 11608509Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: GrantFiled: April 20, 2017Date of Patent: March 21, 2023Assignees: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Caroline Costa Fejoz, Els Verhoeyen, François-Loïc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Publication number: 20190144885Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: April 20, 2017Publication date: May 16, 2019Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche M edicale (INSERM)Inventors: Caroline Costa Fejoz, Els Verhoeyen, François-Loïc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Publication number: 20180371064Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobuType: ApplicationFiled: July 8, 2016Publication date: December 27, 2018Inventors: Floriane FUSIL, Els VERHOEYEN, Thierry DEFRANCE, François-Loïc COSSET
-
Patent number: 9714434Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and a second protein which comprises a ligand of the c-Kit receptor.Type: GrantFiled: June 10, 2013Date of Patent: July 25, 2017Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Francois-Loic Cosset, Els Verhoeyen, Caroline Costa, Cecilia Frecha
-
Patent number: 9249426Abstract: The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:—a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or—a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.Type: GrantFiled: September 28, 2012Date of Patent: February 2, 2016Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Ecole Normale Superieur de LyonInventors: Anais Girard-Gagnepain, Els Verhoeyen, Dimitri Lavillette, Francois-Loic Cosset
-
Publication number: 20140235700Abstract: The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:—a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or—a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.Type: ApplicationFiled: September 28, 2012Publication date: August 21, 2014Inventors: Anais Girard-Gagnepain, Els Verhoeyen, Dimitri Lavillette, François-Loïc Cosset
-
Publication number: 20140017792Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and a second protein which comprises a ligand of the c-Kit receptor.Type: ApplicationFiled: June 10, 2013Publication date: January 16, 2014Inventors: Francois-Loic COSSET, Els Verhoeyen, Caroline Costa, Cecilia Frecha
-
Patent number: 8557573Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: —a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and —a second protein which comprises a ligand of the c-Kit receptor.Type: GrantFiled: July 23, 2008Date of Patent: October 15, 2013Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: François-Loïc Cosset, Els Verhoeyen, Caroline Costa, Cecilia Frecha
-
Publication number: 20100247497Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: —a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and —a second protein which comprises a ligand of the c-Kit receptor.Type: ApplicationFiled: July 23, 2008Publication date: September 30, 2010Inventors: François-Loïc Cosset, Els Verhoeyen, Carollne Costa, Cecilia Frecha